Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term follow-up of bel-sar in early choroidal melanoma after AU-011-301
2025-524405-33-00Phase 3Authorised
- Sponsor
- Aura Biosciences, Inc.
- Start
- Sep 2026
- Modality
- Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Recombinant Proteins and Enzymes, Nanoparticles → Drug Delivery Systems
- Countries
- 14
01
Overview
Phase 3, open-label trial of belzupacap sarotalocan in choroidal melanoma (2 arms), sponsored by Aura Biosciences, Inc. Primary endpoints: Incidence of AEs/SAEs and Time to tumor progression. Planned start Sep 2026; status: authorised.
02
Drugs
belzupacap sarotalocan
03
Conditions
choroidal melanoma
Beyond the preview
Go deeper on 2025-524405-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524405-33-00.